3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
2
Active not recruiting
2
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
492
Pancreatic Neoplasms
387
Carcinoma, Hepatocellular
261
Colonic Neoplasms
214
Stomach Neoplasms
200
Rectal Neoplasms
190
Esophageal Neoplasms
157
Neoplasms
139
Carcinoma, Non-Small-Cell Lung
133
Liver Neoplasms
129
Neoplasm Metastasis
124
Breast Neoplasms
102
Cholangiocarcinoma
94
Melanoma
85
Ovarian Neoplasms
79
Lung Neoplasms
72
Squamous Cell Carcinoma of Head and Neck
57
Carcinoma, Renal Cell
57
Gastrointestinal Neoplasms
55
Sarcoma
46
Biliary Tract Neoplasms
39
Prostatic Neoplasms
36
Head and Neck Neoplasms
36
Esophageal Squamous Cell Carcinoma
36
Adenocarcinoma Of Esophagus
36
Urinary Bladder Neoplasms
33
Adenocarcinoma
33
Uterine Cervical Neoplasms
31
Triple Negative Breast Neoplasms
31
Gastrointestinal Stromal Tumors
31
Interventions
SLC-0111
1
IFL protocol
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Metastatic Pancreatic Ductal Adenocarcinoma
×
Gastrointestinal
×
Clear all
NCT03450018
2024-05-24
SLC-0111-17-01
British Columbia Cancer Agency
Phase 1/2
Terminated
6 enrolled
NCT03331640
2022-01-11
PANTHEON
AIO-Studien-gGmbH
Phase 2
Terminated
67 enrolled